

FDA Drug Approvals

Each month the FDA approves new medications, and below is a highlight of the most relevant new approvals and/or drugs which have the potential to impact your prescription plan. While the medications below have been evaluated and approved by the FDA, they may not enter the marketplace for several weeks or months. Therefore, pricing information for these medications is typically unavailable at the time of approval.

New Brand Approvals			
Drug Name	Uses/Treatment	Pricing Information	Other Information
Siliq (brodalumab)	Treatment of <u>moderate to severe plaque psoriasis</u> in adults who have failed or lost response to other systemic therapies.	Pricing information not yet available	<ul style="list-style-type: none"> • Drug Information: Siliq is available as a 210 mg single-dose prefilled syringe injected subcutaneously every two weeks following initiation. • Formulary Management: Considered non-preferred upon market entry. • Control Trak: Subject to Max Dollar and Max Dose edits. • BIC SpecialtyRx: Comprehensive clinical management and competitive discounts via MedTrak's BIC Specialty Pharmacy Network.
Emflaza (deflazacort)	Treatment of <u>Duchenne muscular dystrophy</u> in patients 5 years of age and older.	Dosing is weight-based and total costs will vary amongst patients	<ul style="list-style-type: none"> • Drug Information: Emflaza is the first steroid approved in the U.S. for specific use in the treatment of Duchenne muscular dystrophy (DMD). • Formulary Management: Considered non-preferred upon market entry. • Control Trak: Subject to Max Dollar and Max Dose edits. • BIC SpecialtyRx: Comprehensive clinical management and competitive discounts via MedTrak's BIC Specialty Pharmacy Network.
Qtern (dapagliflozin/saxagliptin)	Treatment of <u>type 2 diabetes</u> in adults as an adjunct to diet and exercise.	Pricing information not yet available	<ul style="list-style-type: none"> • Drug Information: Qtern is a combination of previously approved Farxiga and Onglyza. • Formulary Management: Considered non-preferred upon market entry. • Control Trak: Subject to Max Dollar and Max Dose edits. • Diabetes CareTrakRx: Qtern will be assessed for potential inclusion and management within MedTrak's Diabetes CareTrakRx program.